BrainsWay Ltd. (NASDAQ:BWAY) is a prominent player in the field of noninvasive neurostimulation treatments, focusing on mental health disorders. The company is known for its advanced brain stimulation technologies, particularly transcranial magnetic stimulation (TMS). BWAY is set to undergo a stock split on March 3, 2026, where shareholders will receive 2 shares for every 1 share they currently hold.
The stock split is a strategic move that could make BWAY's shares more accessible to a broader range of investors. Currently, BWAY's stock is priced at $24.12, with a market capitalization of approximately $487.3 million. The stock has shown volatility, with a 52-week high of $26.63 and a low of $7.84, indicating potential for growth.
In addition to the stock split, BrainsWay is expanding its presence in the North American mental health sector. The company has entered a strategic equity financing agreement with BrainStim Health Inc., investing $1 million initially, with the possibility of an additional $1.5 million. This investment is structured as a preferred, annually compounding security, highlighting BWAY's commitment to growth.
Furthermore, BrainsWay has achieved a significant milestone in TMS therapy coverage. Evernorth Behavioral Health, part of the Cigna Group, will no longer require prior authorization for TMS treatments starting March 6, 2026. This change is expected to improve patient access to TMS therapy, benefiting over 18 million individuals across 12 states.
BWAY's strategic initiatives, including the stock split and expansion in North America, position the company for future growth. The elimination of prior authorization for TMS treatments by Evernorth is a positive development, likely to enhance the company's reputation and accessibility in the mental health sector.
